About Us

Contact Us

Home About Us Product News Order Career Contact


           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd 


Product Indentification

Name:   Tg-101348
Synonyms:   N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide;TG-101348
CAS Registry Number:   936091-26-8
Molecular Formula:   C27H36N6O3S
Molecular Weight:    524.68
Molecular Structure:    



                     In stock!



                    Purity: 99%



                    Storage: 4 deg.                 



                    For Research Use Only






Related  JAK inhibitors:


                             LY 2784544|1229236-86-5                                                    Ruxolitinib|941678-49-5 


                            1056634-68-4|CYT387                                                           CP 690550|477600-75-2


                            AZ960|905586-69-8                                                              AT9283|896466-04-9


                            AG 490|133550-30-8                                                             INCB 018424|1092939-17-7


                           111358-88-4|Lestaurtinib                                                935666-88-9|AZD-1480





Related pages:


     Search Tg-101348 in google
     Search CAS 936091-26-8  in google
     Search C27H36N6O3S  in google


Related info:


         TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM and shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation. In treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo responses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden assessed by quantitative genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.





Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved